Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ER 100

Next Previous
Drug Profile

ER 100

Alternative Names: ER-100

Latest Information Update: 17 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harvard University
  • Developer Life Biosciences
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ischaemic optic neuropathy; Open-angle glaucoma

Most Recent Events

  • 02 Mar 2026 Phase-I clinical trials in Ischaemic-optic-neuropathy in USA (Intravitreous) (NCT07290244)
  • 02 Mar 2026 Phase-I clinical trials in Open-angle glaucoma in USA (Intravitreous) (NCT07290244)
  • 29 Jan 2026 US FDA approves IND application for ER 100 in Non-arteritic anterior ischaemic optic neuropathy (NAION) and open angle glaucoma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top